These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 21267600)

  • 1. Can bisphosphonates play a role in the treatment of children with chronic kidney disease?
    Haffner D; Fischer DC
    Pediatr Nephrol; 2011 Dec; 26(12):2111-9. PubMed ID: 21267600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphophonates in CKD patients with low bone mineral density.
    Liu WC; Yen JF; Lang CL; Yan MT; Lu KC
    ScientificWorldJournal; 2013; 2013():837573. PubMed ID: 24501586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonate use in chronic kidney disease: association with adynamic bone disease in a bone histology series.
    Amerling R; Harbord NB; Pullman J; Feinfeld DA
    Blood Purif; 2010; 29(3):293-9. PubMed ID: 20090316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmaceutical therapy of bone metabolism disorders in chronic kidney disease mineral bone disorder (CKD-MBD) with special respect to antiresorptive substances].
    Lehmann G; Wolf G
    Z Rheumatol; 2014 May; 73(4):329-34. PubMed ID: 24811357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates in renal osteodystrophy.
    Fan SL; Cunningham J
    Curr Opin Nephrol Hypertens; 2001 Sep; 10(5):581-8. PubMed ID: 11496050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Osteoporosis and chronic kidney disease: review and new therapeutic strategies].
    Sessa C; Galeano D; Alessandrello I; Aprile G; Distefano G; Ficara V; Giglio E; Musumeci S; Pocorobba B; Zuppardo C; Musso S; Granata A
    G Ital Nefrol; 2019 Jul; 36(4):. PubMed ID: 31373465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue.
    Toussaint ND; Elder GJ; Kerr PG
    Clin J Am Soc Nephrol; 2009 Jan; 4(1):221-33. PubMed ID: 18987295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoporosis, bone mineral density and CKD-MBD: treatment considerations.
    Bover J; Bailone L; López-Báez V; Benito S; Ciceri P; Galassi A; Cozzolino M
    J Nephrol; 2017 Oct; 30(5):677-687. PubMed ID: 28432640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The possible use of bisphosphonates in the treatment of renal osteodystrophy.
    Malluche HH
    Clin Nephrol; 1992; 38 Suppl 1():S87-91. PubMed ID: 1295713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of reduced bone density with ibandronate in dialysis patients.
    Bergner R; Henrich D; Hoffmann M; Schmidt-Gayk H; Lenz T; Upperkamp M
    J Nephrol; 2008; 21(4):510-6. PubMed ID: 18651540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonate therapy in CKD: the current state of affairs.
    Damasiewicz MJ; Nickolas TL
    Curr Opin Nephrol Hypertens; 2020 Mar; 29(2):221-226. PubMed ID: 31833938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Use of bisphosphonates in chronic kidney disease].
    Torregrosa JV; Ramos AM
    Nefrologia; 2010; 30(3):288-96. PubMed ID: 20514097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of osteoporosis in chronic kidney disease and end-stage renal disease.
    Miller PD
    Curr Osteoporos Rep; 2005 Mar; 3(1):5-12. PubMed ID: 16036095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The efficacy and safety of bisphosphonate for patients with kidney disease].
    Hiramatsu R; Ubara Y
    Clin Calcium; 2016 Sep; 26(9):1319-24. PubMed ID: 27561347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The treatment of the patient presenting with chronic kidney disease (CKD) and fragility fractures].
    Giusti A; Fusaro M
    G Ital Nefrol; 2017 Dec; 34(Nov-Dec):. PubMed ID: 29207226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiating the causes of adynamic bone in advanced chronic kidney disease informs osteoporosis treatment.
    Haarhaus M; Evenepoel P; ;
    Kidney Int; 2021 Sep; 100(3):546-558. PubMed ID: 34102219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of osteoporosis in renal insufficiency.
    Schipper LG; Fleuren HW; van den Bergh JP; Meinardi JR; Veldman BA; Kramers C
    Clin Rheumatol; 2015 Aug; 34(8):1341-5. PubMed ID: 25630310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal osteodystrophy and aging.
    Sherrard DJ
    Semin Nephrol; 2009 Nov; 29(6):636-42. PubMed ID: 20006795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of experimental renal osteodystrophy with pamidronate.
    Jokihaara J; Pörsti IH; Kööbi P; Jolma PM; Mustonen JT; Saha HH; Sievänen H; Kannus P; Iwaniec UT; Turner RT; Järvinen TL
    Kidney Int; 2008 Aug; 74(3):319-27. PubMed ID: 18463610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What Animal Models Have Taught Us About the Safety and Efficacy of Bisphosphonates in Chronic Kidney Disease.
    Allen MR; Aref MW
    Curr Osteoporos Rep; 2017 Jun; 15(3):171-177. PubMed ID: 28432595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.